Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical use of anti-TLR4 antibody

A technology of use and antibody, applied in the field of pharmaceutical use of anti-TLR4 antibody, can solve the problem of unclear role of soluble partial receptors, etc.

Active Publication Date: 2011-05-04
BIOMERIEUX SA +1
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

TLR4 is known to cooperate with another molecule called MD-2 and together with CD14, a complex involved in the recognition of bacterial lipopolysaccharides (LPSs), leading to NK-κ-B factors in cytokine secretion and inflammatory responses , but the role of the receptor for the soluble portion of the MSRV / HERV-W envelope protein (Env-SU) was not known prior to the present invention

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical use of anti-TLR4 antibody
  • Pharmaceutical use of anti-TLR4 antibody
  • Pharmaceutical use of anti-TLR4 antibody

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0164] in vitro studies

[0165] Materials and methods

[0166] proteins and toxins

[0167] The surface protein of the MSRV envelope (Env-SU) corresponds to the protein sequence of 287 amino acids of the total envelope protein (Env Pv14, GenBank AF331500). The structures and amino acid sequences of EnvPv14 and ENV-SU are shown in Figures 1(a) and 1(b), respectively. The recombinant MSRVEnv-SU protein was expressed in E. coli and purified on an FPLC column. The quality and purity of the protein were further confirmed by mass spectrometry and Western blotting. Casein kinase was used as an autologous negative control. This control protein was produced and purified under the same conditions as Env-SU.

[0168] Detection of the presence of endotoxin in both proteins was performed by the Limulis amebocyte lysate (LAL) assay by the company CleanCells (Bouffere, France). All fractions were below the detection threshold of 5 IU / ml. Staphylococcal endotoxin was obtained from ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

The inventive composition comprises at least one type of antibody selected in a group (i) of anti-Env-SU MSRV / HERV-W antibodies or in a group of anti-TLR4 antibodies specifically linkable with a soluble fraction of an Env protein of MSRV / HERV-W or to a TLR4 receptor of the soluble fraction of the Env protein of MSRV / HERV-W.

Description

Background technique [0001] Over the years, numerous studies have demonstrated the presence of various retroviral and especially endogenous Influential expression of recording virus (HERV). HERVs share homology to known animal retroviruses and may arise from their integration into the human germline. In the human genome, the sequences of these HERVs are usually incomplete, although full proviral sequences have been identified. [0002] Retroviral particles have been isolated from pial cell cultures of MS patients [4]. Studies of these particles have revealed that they are a new family of endogenous retroviruses (HERV-W) with gene sequences homologous to human DNA [2, 5, 6]. Different groups have demonstrated the presence of MSRV in patient serum and / or cerebrospinal fluid (CSF) (7-9) and demonstrated that viral load correlates with disease progression [10]. It was later proved that MSRV and its envelope protein have superantigen (SAg) type, T lymphocyte-mediated pro-infla...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/28C07K16/10
CPCA61K2039/505C07K16/1036C07K16/28A61P21/00A61P25/00A61P25/18A61K38/17
Inventor 帕特斯·玛什亚历山大·罗兰伊芙琳·茹婉-玛什埃尔维·贝鸿
Owner BIOMERIEUX SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com